Ketoprofen

Ketoprofen

SCHEMBL3843886

CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1.CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PTGS1PTGS2

The experimentally established mechanism targets of Ketoprofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 known ✓ P23219 6/20 1.00
PTGS2 known ✓ P35354 6/20 1.00
MAPT P10636 5/20 1.00
SMN1; SMN2 Q16637 3/20 1.00
ALDH1A1 P00352 3/20 1.00
LMNA P02545 3/20 1.00
CXCR1 P25024 2/20 1.00
CXCR2 P25025 2/20 1.00
CYP3A4 P08684 2/20 1.00
RECQL P46063 1/20 1.00
KDM4E B2RXH2 1/20 1.00
HPGD P15428 1/20 1.00
MAPK1 P28482 1/20 1.00
PMP22 Q01453 1/20 1.00
SLC22A6 Q4U2R8 1/20 1.00
HSD17B10 Q99714 1/20 1.00
CXCL8 P10145 1/20 1.00
THPO P40225 1/20 1.00
HIF1A Q16665 1/20 1.00
HTT P42858 3/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ketoprofen SCHEMBL2896 1.00 PTGS1 (1.00) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
R-Ketoprofen SCHEMBL195303 1.00 PTGS1 (1.00) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
Ketoprofen SCHEMBL8577572 1.00 PTGS1 (1.00) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
Dexketoprofen SCHEMBL29396875 1.00 PTGS1 (1.00) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
Ketoprofen SCHEMBL16757741 1.00 PTGS1 (1.00) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
Ketoprofen SCHEMBL679920 1.00 PTGS1 (1.00) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
Dexketoprofen SCHEMBL66987 1.00 PTGS1 (1.00) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
R-Ketoprofen SCHEMBL29353694 1.00 PTGS1 (1.00) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
Ketoprofen SCHEMBL8754790 1.00 PTGS1 (1.00) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
Ketoprofen SCHEMBL23391019 0.98 PTGS1 (0.97) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1236758-C Slow-releasing injection contg. hydrocastor oil/medicine (for treatment) solid dispersion microparticle WANG YUWAN (CN) 2006-01-18 CN claimed
CN-1583174-A Long-term injection containing ethylcellulose and fatty acid ester WANG YUWAN (CN) 2005-02-23 CN claimed
CN-1533764-A Slow release injection preparation containing non sterol anti inflammation medicine 王玉万 2004-10-06 CN claimed
CN-1490009-A Sustained release injection containing medicine against coccindian 王玉万 2004-04-21 CN claimed
CN-1461639-A Slow-releasing injection contg. hydrocastor oil/medicine (for treatment) solid dispersion microparticle WANG YUWAN (CN) 2003-12-17 CN claimed
CN-1444925-A Long acting injection containing ethyl cellulose for animal WANG YUWAN (CN) 2003-10-01 CN claimed
US-20210244742-A1 COMPOSITION COMPRISING A THERAPEUTIC AGENT AND A RESPIRATORY STIMULANT AND METHODS FOR THE USE THEREOF HSU JOHN (US) 2021-08-12 US disclosed
WO-2021110085-A1 METHOD FOR ASSOCIATING WITH EXPRESSION LEVEL OF AKR1C3 ENZYME VIA CONTENT OF PROSTAGLANDIN, AND USE OF SCREENING FOR DRUG ADMINISTRATION 深圳艾欣达伟医药科技有限公司 2021-06-10 WO disclosed
US-10653700-B2 Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof HSU JOHN (US) 2020-05-19 US disclosed
US-20180296565-A1 COMPOSITION COMPRISING A THERAPEUTIC AGENT AND A RESPIRATORY STIMULANT AND METHODS FOR THE USE THEREOF HSU JOHN (US) 2018-10-18 US disclosed
US-10004749-B2 Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof HSU JOHN (US) 2018-06-26 US disclosed
US-20170020885-A1 Composition Comprising a Therapeutic Agent and a Respiratory Stimulant and Methods for the Use Thereof HSU JOHN (US) 2017-01-26 US disclosed
US-20160175436-A1 COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES VICUS THERAPEUTICS LLC (US) 2016-06-23 US disclosed
EP-0215423-A2 Transdermally resorbable aqueous compositions of arylpropionic-acid derivatives and process for their preparation Dolorgiet GmbH & Co. KG (DE) 1987-03-25 EP disclosed
EP-0201828-A2 Components for therapeutical drug delivery devices BAYER AG (DE) 1986-11-20 EP disclosed
US-4623346-A Isobutylene polymer active compound release systems BAYER AKTIENGESELLSCHAFT (DE) 1986-11-18 US disclosed
EP-0132690-A1 Thermoplastics containing antiphlogistics Troponwerke GmbH & Co. KG (DE) 1985-02-13 EP disclosed
US-4292319-A MIXTURE WITH AN ANTIULCER AGENT BOEHRINGER INGELHEIM GMBH (DE) 1981-09-29 US disclosed
US-4256747-A ANTIINFLAMMATORY AGENTS, PYRIDO/2,3B//1,4/BENZODIAZEPIN-6-ONES BOEHRINGER INGELHEIM GMBH (DE) 1981-03-17 US disclosed
US-4154833-A INDOMETHACIN (1-(4-CHLOROBENZOYL)-5-METHOXY-2-METHYL-1H-INDOLE-3-ACETIC ACID) WITH PIRENZEPINE (5,11-DIHYDRO-11-((4-METHYL-1-PIPERAZINYL)-ACETYL)-6H-PYRIDO(2,3 -B)(1,4)BENZODIAZEPIN-6-ONE) BOEHRINGER INGELHEIM GMBH (DE) 1979-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170020885-A1 Composition Comprising a Therapeutic Agent and a Respiratory Stimulant and Methods for the Use Thereof OPRM1, OPRL1, OPRK1 PTGS1 552/4885PTGS2 1133/4885MAPT 3370/4885
US-20210244742-A1 COMPOSITION COMPRISING A THERAPEUTIC AGENT AND A RESPIRATORY STIMULANT AND METHODS FOR THE USE THEREOF OPRM1, OPRL1, OPRK1 PTGS1 753/4885PTGS2 1125/4885MAPT 2759/4885
US-20180296565-A1 COMPOSITION COMPRISING A THERAPEUTIC AGENT AND A RESPIRATORY STIMULANT AND METHODS FOR THE USE THEREOF OPRM1, OPRL1, OPRK1 PTGS1 552/4885PTGS2 1133/4885MAPT 3370/4885
US-10004749-B2 Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof OPRM1, OPRL1, OPRK1 PTGS1 552/4885PTGS2 1133/4885MAPT 3370/4885
US-10653700-B2 Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof OPRM1, OPRL1, OPRK1 PTGS1 552/4885PTGS2 1133/4885MAPT 3370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.